\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}



\usepackage{float}








\begin{document}

\title{Commentary on the European Medicines Agency's extended mandate -
Protecting public health in times of crisis and improving availability
of medicines and medical devices}



\author[1]{Inga Abed}%
\author[1]{Rosa Gonzalez-Quevedo}%
\author[1]{Manuela Mura}%
\author[1]{Monica Dias}%
\author[1]{Silvy Da Rocha Dias}%
\author[2]{Juan (EMA PAPERS ONLY) Garcia Burgos}%
\affil[1]{European Medicines Agency}%
\affil[2]{European Medical Agency}%


\vspace{-1em}



  
  \date{May 17, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
The European Medicines Agency (EMA) started operating under its new
legal mandate on 1 April 2022. The mandate brings new responsibilities
to the Agency in three different areas: * Reinforcement of the role and
activities of the EMA pandemic Task Force(which is now known as the
Emergency Task Force (ETF)). * A stronger role of EMA in the monitoring
of shortages of critical medicines, medical devices and in-vitro
diagnostics, both in anticipation of and during a crisis. * A more
coordinated mechanism of European Union (EU) experts advice on medical
devices classified as high-risk (class IIa and III or class D (1)) and
in-vitro diagnostic medical devices. Here we consider the impact of the
COVID-19 pandemic on the operations of EMA and the European medicines
regulatory network, and how EMA's new mandate will strengthen the
Agency's and the Network's ability to face crises. EMA's extended
mandate brings clear benefits in terms of response to public health
emergencies at EU level, which ranges from improvements in crisis
management to avoiding medicine shortages and improving access to
diagnostics and medical devices that are safe and conform to their
expected function.%
\end{abstract}%



\sloppy


\textbf{Hosted file}

\verb`BJCP_extended_mandate.docx`  available at \url{https://authorea.com/users/508335/articles/586244-commentary-on-the-european-medicines-agency-s-extended-mandate-protecting-public-health-in-times-of-crisis-and-improving-availability-of-medicines-and-medical-devices}

\selectlanguage{english}
\FloatBarrier
\end{document}

